Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rational discovery of a highly novel and selective mTOR inhibitor.
Jin S, Mikami S, Scorah N, Chen Y, Halkowycz P, Shi L, Kahana J, Vincent P, de Jong R, Atienza J, Fabrey R, Zhang L, Lardy M. Jin S, et al. Among authors: vincent p. Bioorg Med Chem Lett. 2019 Nov 1;29(21):126659. doi: 10.1016/j.bmcl.2019.126659. Epub 2019 Sep 3. Bioorg Med Chem Lett. 2019. PMID: 31543303
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT, Beebe JS, Berliner MA, Bernardo V, Boehm M, Borzillo GV, Clark T, Cohen BD, Connell RD, Frost HN, Gordon DA, Hungerford WM, Kakar SM, Kanter A, Keene NF, Knauth EA, Lagreca SD, Lu Y, Martinez-Alsina L, Marx MA, Morris J, Patel NC, Savage D, Soderstrom CI, Thompson C, Tkalcevic G, Tom NJ, Vajdos FF, Valentine JJ, Vincent PW, Wessel MD, Chen JM. Arcari JT, et al. Bioorg Med Chem Lett. 2013 May 15;23(10):3059-63. doi: 10.1016/j.bmcl.2013.03.012. Epub 2013 Mar 21. Bioorg Med Chem Lett. 2013. PMID: 23566514
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P. Farrell PJ, et al. Among authors: vincent p. Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341789
Synthesis and structure based optimization of novel Akt inhibitors.
Lippa B, Pan G, Corbett M, Li C, Kauffman GS, Pandit J, Robinson S, Wei L, Kozina E, Marr ES, Borzillo G, Knauth E, Barbacci-Tobin EG, Vincent P, Troutman M, Baker D, Rajamohan F, Kakar S, Clark T, Morris J. Lippa B, et al. Among authors: vincent p. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3359-63. doi: 10.1016/j.bmcl.2008.04.034. Epub 2008 Apr 15. Bioorg Med Chem Lett. 2008. PMID: 18456494
Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD. Schroeder MC, et al. Among authors: vincent pw. J Med Chem. 2001 Jun 7;44(12):1915-26. doi: 10.1021/jm0004291. J Med Chem. 2001. PMID: 11384237
Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM, Murray DK, Elliott WL, Fry DW, Nelson JA, Showalter HD, Roberts BJ, Vincent PW, Denny WA. Thompson AM, et al. Among authors: vincent pw. J Med Chem. 1997 Nov 21;40(24):3915-25. doi: 10.1021/jm970366v. J Med Chem. 1997. PMID: 9397172
Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA. Rewcastle GW, et al. Among authors: vincent pw. J Med Chem. 1998 Feb 26;41(5):742-51. doi: 10.1021/jm970641d. J Med Chem. 1998. PMID: 9513602
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ. Smaill JB, et al. Among authors: vincent pw. J Med Chem. 1999 May 20;42(10):1803-15. doi: 10.1021/jm9806603. J Med Chem. 1999. PMID: 10346932
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM. Showalter HD, et al. Among authors: vincent pw. J Med Chem. 1997 Feb 14;40(4):413-26. doi: 10.1021/jm960689b. J Med Chem. 1997. PMID: 9046331
1,060 results